abrdn Life Sciences Investors Profit Margin

abrdn Life Sciences Investors (HQL) currently reports a profit margin of 136.37% as of March 2026. That compares with 185.45% in the prior-year period — down 26.5% year over year. That is above the sector sector average of 21.34%. Use the charts on this page to explore abrdn Life Sciences Investors's profit margin history and peer comparisons.

abrdn Life Sciences Investors's profit margin decreased from 185.45% to 136.37% — a 26.5% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

abrdn Life Sciences Investors's profit margin of 136.37% is higher than the its sector sector average of 21.34%. That is roughly 539.0% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but abrdn Life Sciences Investors's current 136.37% should be judged against industry norms (sector average: 21.34%) and against HQL's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 136.37%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 21.34%. From there, open related valuation or income-statement pages for abrdn Life Sciences Investors, and consider following HQL for alerts when major investors trade the stock.